Titan Biotech 1:4 Bonus Shares: Key Dates Explained

Titan Biotech’s 1:4 bonus shares are the talk of Indian markets this week, with the record date just days away. The biotech manufacturer’s board has approved issuing one fully paid-up bonus equity share for every four shares held, a corporate action that follows a standout quarter and a three-year run that delivered roughly 453% returns. If you hold — or plan to buy — Titan Biotech shares, the timeline below is what matters.

What Titan Biotech’s 1:4 bonus issue means

Under the 1:4 bonus issue, every shareholder holding 4 shares on the record date receives 1 additional fully paid-up equity share of Rs 2 face value. In practice, 40 shares become 50 — no extra payment required. The company will allot 1,03,29,625 bonus equity shares in total, funding the roughly Rs 2.07 crore cost from free reserves and the share premium account. To accommodate the issue, the board also approved an increase in the authorised share capital.

Bonus issues are typically a signal of board confidence: rather than sitting on accumulated reserves, the company converts them into share capital, rewarding existing shareholders while improving the stock’s liquidity in the market.

Titan Biotech 1:4 bonus shares: the key dates to know

• Record date — Friday, October 23, 2026: You must hold Titan Biotech shares at the close of this date to qualify for the bonus.
• Deemed date of allotment — Monday, October 26, 2026: The board fixed this as the date the bonus shares are formally allotted.
• New shares begin trading — Tuesday, October 27, 2026: The bonus shares are expected to be listed and tradable from this date.

With the record date falling this Friday, investors had only days left to buy in and qualify — which explains the surge in search interest this week. Note that shares bought on or after the ex-date will not carry the bonus entitlement, so check your broker’s settlement timeline before acting.

The strong Q1 behind the bonus decision

The bonus issue follows a strong June quarter. Titan Biotech reported a 53% jump in standalone net profit, with standalone revenue up 29% to Rs 609.8 crore and basic earnings per share rising to Rs 2.29 from Rs 1.49. Consolidated net profit grew 58% year-on-year to Rs 108.6 crore.

The stock itself has been a multibagger: it closed 1.57% higher at Rs 406.90 on the BSE after the announcement, taking its market capitalisation to about Rs 1,681.25 crore, and it has delivered roughly 453% returns over the past three years. The company manufactures biological and specialty products, including collagen and skincare ingredients — segments riding strong demand in India and abroad.

What bonus shares change — and what they don’t

A bonus issue increases the number of shares outstanding but does not change the company’s underlying value: on the ex-bonus date, the share price typically adjusts downward in proportion to the new share count, so your total holding value stays roughly the same. What does change is liquidity — more shares in circulation usually means tighter spreads and easier trading — and the psychological effect of a lower per-share price.

For long-term investors, the real signal is the board’s willingness to capitalise reserves after a strong quarter. For traders, the key risk is short-term volatility around the record and ex-dates, when the stock often sees elevated volumes. Keep an eye on unusual activity on Meyka’s India unusual volume page in the run-up to October 23.

How to track Titan Biotech around the record date

Investors watching the bonus timeline can follow the stock on Meyka’s screener for Indian stocks and check the India earnings calendar for upcoming results that could move the price further. Titan Biotech’s board has already shown it rewards shareholders when results are strong — the Q1 numbers suggest that trend could continue.

This article is for informational purposes only and does not constitute financial advice.

Sources: Zee Business and Livemint.